| Manufacturers/sponsors |
Allos Therapeutic (pralatrexate) |
| Others |
Department of Health |
| |
NHS Camden |
| |
NHS Middlesbrough |
| |
Welsh Assembly Government |
| Patient/carer groups |
Afiya Trust |
| |
African Caribbean Leukaemia Trust (ACLT) |
| |
Anthony Nolan Bone Marrow Trust |
| |
Black Health Agency |
| |
CANCERactive |
| |
Cancer Black Care |
| |
Cancer 52 |
| |
Counsel and Care |
| |
Equalities National Council |
| |
Helen Rollason Heal Cancer Charity |
| |
Leukaemia CARE |
| |
Leukaemia Society (UK) |
| |
Lymphoma Association |
| |
Macmillan Cancer Support |
| |
Maggie’s Centres |
| |
Marie Curie Cancer Care |
| |
Muslim Council of Britain |
| |
Muslim Health Network |
| |
Rarer Cancers Foundation |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| |
Sue Ryder Care |
| |
Tenovus |
| Professional groups |
Association of Cancer Physicians |
| |
British Association for Services to the Elderly |
| |
British Committee for Standards in Haematology |
| |
British Geriatrics Society |
| |
British Psychosocial Oncology Society |
| |
British Society for Haematology |
| |
Cancer Networks Pharmacists Forum |
| |
Cancer Research UK |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
United Kingdom Clinical Pharmacy Association |
| |
United Kingdom Oncology Nursing Society |
| Associated guideline groups |
National Collaborating Centre for Cancer |
| Associated public health groups |
None |
| Comparator manufacturers |
Actavis UK (epirubicin, fludarabine, gemcitabine, prednisolone) |
| |
Alliance Pharmaceuticals (prednisolone) |
| |
Amdipharm (prednisolone) |
| |
Auden McKenzie (Pharma Division) (dexamethasone) |
| |
Baxter (cyclophosphamide, ifosfamide) |
| |
Bristol-Myers Squibb (carboplatin, cisplatin, etoposide) |
| |
Chemidex pharma (dexamethasone) |
| |
Eli Lilly and Company (gemcitabine) |
| |
Genzyme Therapeutics (fludarabine) |
| |
Goldshield Critical Care (cisplatin) |
| |
Hameln Pharmaceuticals (epirubicin) |
| |
Hospira UK (carboplatin, cisplatin, cytarabine, epirubicin, etoposide, fludarabine, gemcitabine) |
| |
Medac UK (epirubicin, etoposide, gemcitabine, lomustine) |
| |
Merck Sharp & Dohme (dexamethasone) |
| |
Mylan (epirubicin, gemcitabine) |
| |
Pfizer (cisplatin, cyclophosphamide, cytarabine, epirubicin, methylprednisolone) |
| |
Rosemont Pharmaceuticals (dexamethasone) |
| |
Sandoz (carboplatin, cisplatin, epirubicin, fludarabine, gemcitabine) |
| |
Sigma Pharmaceuticals (methylprednisolone) |
| |
Sun Pharmaceuticals UK (carboplatin, gemcitabine) |
| |
Teva UK (carboplatin, cisplatin, epirubicin, etoposide, fludarabine, gemcitabine) |
| |
Wockhardt UK (carboplatin, cisplatin, epirubicin, fludarabine, gemcitabine) |
| Evidence Review Group |
British Medical Journal (BMJ) |
| |
National Institute for Health Research Health Technology Assessment Programme |
| General |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Commissioning Support Appraisals Service |
| |
Department of Health,Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
NHS Alliance |
| |
NHS Commercial Medicines Unit |
| |
NHS Confederation |
| |
Public Health Wales NHS Trust |
| |
Scottish Medicines Consortium |
| Relevant research groups |
British National Lymphoma Investigation |
| |
Elimination of Leukaemia Fund |
| |
Institute of Cancer Research |
| |
Leukaemia Busters |
| |
Leukaemia & Lymphoma Research |
| |
MRC Clinical Trials Unit |
| |
National Cancer Research Institute |
| |
National Cancer Research Network |
| |
National Institute for Health Research |
| |
Policy Research Institute on Ageing and Ethnicity |
| |
Research Institute of the Care of Older People |